A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults with Selected Advanced Solid Tumors
- Sponsor:
- Apollo Therapeutics
- Sponsor Study ID:
- AP10CP01
- CTO #:
- 104054
- NCT Number:
- NCT06399757
- Phase:
- I/II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Colon; Rectum
- Study Objectives:
- Evaluate the safety of APL-5125. Determine recommended phase 2 dose (RP2D) levels of APL-5125. Estimate the maximum tolerated dose (MTD) of APL-5125 in participants with selected advanced solid tumors.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Lockhart, Albert, at lockhara@musc.edu .
- Study Coordinator, Gillam, Erin, at gillame@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina